Clivatuzumab tetraxetan: Updated Phase Ib/II data

Updated data from 37 evaluable patients with previously untreated, inoperable, locally advanced or metastatic pancreatic cancer in an ongoing, open-label Phase Ib/II trial showed that clivatuzumab plus Gemzar gemcitabine led to a 57% disease control rate, with 6 partial responses and 16 cases of stable disease. In 16 patients receiving 12 mCi/m 2 weekly clivatuzumab for 3 weeks, the disease control rate was 69%. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...